Japan's PMDA Issues Guidance to Safeguard Participants in Generic Bioequivalence Trials
The Pharmaceuticals and Medical Devices Agency (PMDA) in Japan has released new guidance aimed at protecting healthy adult volunteers who take part in generic bioequivalence studies.
The document outlines specific safety measures that sponsors should implement, including monitoring protocols, risk assessment procedures, and clear criteria for participant eligibility.
By standardizing these practices, the PMDA seeks to enhance the reliability of bioequivalence data and bolster confidence in the approval of generic medicines.
The agency encourages drug developers to adopt the recommendations to align with international safety standards and streamline the regulatory review process.
This writeup was produced by pharmadog from original reporting by raps.
Original headline: “Asia-Pacific Roundup: Japan’s PMDA shares guidance on assuring safety in generic bioequivalence studies”
read at raps ↗
comments(0)
5-min edit window · permanent after that